Editorial Videos

Graham Goodrich, CCO, Apnimed, points to 2026 as a pivotal year marked by Apnimed’s planned NDA filing for AD109, the build-out of its commercial infrastructure and access strategy, and preparations for a potential FDA decision in early 2027.

Hayley Burgess SVP, Inovalon, talks about how specialty pharmacists are evolving from dispensers into precision-care partners, using integrated data, automation, and AI to personalize therapy decisions.

Graham Goodrich, CCO, Apnimed, positions AD109 as a long-awaited, patient-acceptable therapy for untreated sleep apnea that delivers meaningful improvements in oxygenation, daily functioning, and peace of mind.

Hayley Burgess SVP, Inovalon, touches on integrated care mentioning to the industry's priority of shared real-time data across payers, providers, and pharmacies, can lead to it becoming reality.

Graham Goodrich, CCO, Apnimed, outlines how advances in diagnostics, growing recognition of sleep apnea’s systemic impact, and emerging oral therapies are driving renewed momentum in sleep medicine as Apnimed advances toward commercialization.

Michael O'Rourke, CEO of Re-Vana Therapeutics, touches on Re-Vana's transition from an academic spinout to a fully established biotech, marked by team expansion, facility growth, and validation of its sustained-delivery platform.

Hayley Burgess SVP, Inovalon, talks about how pharmacies preserve efficiency while strengthening patient care by using technology to unify data, streamline workflows, and proactively monitor high-risk patients across care transitions.

Michael O'Rourke, CEO of Re-Vana Therapeutics, frames Re-Vana's early-stage, platform-led model as credible to public-market investors, pointing to clinical validation of sustained biologic delivery and strong collaboration interest.

Hayley Burgess SVP, Inovalon, talks about rising data fragmentation, access barriers, and adherence risks pushing specialty pharmacies to adopt integrated, end-to-end platforms that consolidate clinical, operational, and patient data.

Michael O' Rourke , CEO Re-Vana Therapeutics, discusses positioning Re-Vana as a long-term platform partner by leveraging its sustained-delivery hydrogel technologies to support both internally developed assets and external pharma collaborations.

Angela Schwab, founder and CEO of Trialynx, discusses the importance of designing trials around patients and how doing so doesn’t have to come at the cost of generating good data.

Hayley Burgess SVP, Inovalon, touches on Specialty pharmacies grappling with surging drug complexity and costs while navigating fragmented data systems, access hurdles, and prior authorization demands that strain pharmacists’ abilities.

In the third part of her conversation with PharmExec, Trialynx founder and CEO Angela Schwab discusses the causes and solutions for high failure rates in clinical trials.

Trialynx founder and CEO Angela Schwab continues her conversation with PharmExec and explains the effective ways that AI is being used to tackle common problems with clinical trial design.

Angela Schwab, founder and CEO of Trialynx, discusses the current state of AI in the pharmaceutical industry and why it’s important for companies to demonstrate the true value of their AI-based products.

In the third and final part of her conversation with Pharmaceutical Executive, discusses the ways that regulatory agencies in major global markets are acting in similar ways to have a positive impact on the biosimilars market.

In the second part of her conversation with Pharmaceutical Executive, Gillian Woollett, VP and head of regulatory strategy at Samsung Bioepis, explains the direct impact changes at FDA have on the biosimilar space.

Gillian Woollett, VP and head of regulatory strategy at Samsung Bioepis, discusses how the current regulatory climate is the result of years of work.

In the final part of this conversation, Dr. Bruce Leuchter, CEO of Neurvati Neurosciences, discusses new programs at FDA and how the neuroscience space is benefitting.

Jay Bregman, co-founder of Andel, closes out our conversation by explaining the impact government programs will have on GLP-1 coverage.

Dr. Bruce Leuchter, CEO of Neurvati Neurosciences, explains why psychedelics continues to be an area of interest.

Dr. Bruce Leuchter, CEO of Neurvati Neurosciences, continues his conversation, this time looking to the upcoming year in neuroscience.

In the final part of our conversation with Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, he discusses how FDA’s new program may or may not impact manufacturing pipelines.

In the second part of our conversation, Andel co-founder Jay Bregman how new GLP-1 options hitting the market will amplify existing coverage problems for the near future.

In the first part of this video, Dr. Bruce Leuchter, CEO of Neurvati Neuroscience, discusses which areas of neuroscience are exciting investors.

Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, continues his conversation about FDA’s Priority Review Voucher Program, and explains what the industry can learn from the announced participants.

Jay Bregman, co-founder of Andel, the cost and operational complexity of covering GLP-1 medications.

In the first part of our conversation with Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, he provides a broad overview of the possible positive and negative impacts of FDA’s Priority Review Voucher Program.